Q2 FY27 loss widens as demand and exports weaken

Compliance View source PDF Explain this filing

ASTEC · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.8%Reaction day

₹650.00

prior close

₹630.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.7%-2.5% vs market

Pesticides & Agrochemicals peers, median of 27sector+1.2%-2.0% vs sector

On the reaction day the stock moved 2.5 pts less than Nifty Microcap 250 and 2.0 pts less than its Pesticides & Agrochemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.1

10m

-1.6

15m

-0.3

30m

+3.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.8+1.7-2.5+1.2-2.0

Next day

-7.9pendingpending+2.3-10.2

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pesticides & Agrochemicals peers, median of 27Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Astec LifeSciences reported unaudited Q2 FY27 results. Income fell 3% to Rs 72.6 crore, the EBITDA loss widened to Rs 19.2 crore from Rs 5.6 crore, and the net loss widened to Rs 37.4 crore from Rs 24.4 crore. H1 income fell 6% to Rs 156.9 crore, with a Rs 56.1 crore net loss. Weak demand, channel stocks, lower exports and cost pressures hurt results; CDMO revenue rose 15% to Rs 15 crore.

Likely market impact

Negative: weaker sales and deeper operating losses may pressure the stock, despite 15% CDMO growth and a slightly lower H1 net loss.